Valeant Pharmaceuticals Intern… (NYSE:VRX) - Page 2

Top Analyst Upgrades and Downgrades: Cree, Home Depot, Kimberly-Clark, Microsoft, Oracle, Valeant, Valero and More

Stocks were indicated to open higher (+9 on S&P 500 and +100 Dow Jones Industrial Average) after continued gains so far in 2018. Investors are looking to position their portfolios ...
Read Full Story »

Valeant Pharmaceuticals Well on the Road to Recovery After Bausch + Lomb Distribution Deal

Valeant Pharmaceuticals International Inc. (NYSE: VRX) shares made a spectacular crash over the course of 2015 to 2017, and it looks like they now may be on the path to ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Delta Air Lines, Express Scripts, Form Factor, Marathon Oil, Under Armour, Valeant Pharmaceuticals and More

The futures traded higher this Friday morning as investors looked to wrap up a solid week on Wall Street. With just two weeks left in 2017, we may start to ...
Read Full Story »

Valeant Earnings Soar on Tax Benefit

Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported third-quarter 2017 results before markets opened Tuesday. The company reported quarterly diluted earnings per share (EPS) of $3.69 and revenues of $2.22 billion. ...
Read Full Story »

CenturyLink, Disney, JC Penney and More Major Earnings Coming This Week

The earnings reporting season has mostly come and gone, but there are still some major companies posting results this week. 24/7 Wall St. has put together a preview of a ...
Read Full Story »

Top Biopharma Events Coming by the End of 2017

As the markets continue to hit all-time highs, biotech and pharmaceutical companies have been part of these massive gains. There is a very positive sentiment in the health care sector ...
Read Full Story »

Valeant Pharmaceuticals Gets Boost From FDA Update

Shares of Valeant Pharmaceuticals International Inc. (NYSE: VRX) saw a handy gain on Thursday after the company provided an update from the U.S. Food and Drug Administration (FDA). Specifically, the ...
Read Full Story »

Is This the Turnaround Valeant Pharma Has Been Waiting For?

Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported its second-quarter financial results before the markets opened on Tuesday. This stock is known for its fall from grace, trading above $250 per ...
Read Full Story »

Disney, Snap and More of the Top Earnings to Watch This Week

24/7 Wall St. has put together a preview of a few major companies scheduled to report their quarterly results this coming week. The Dow Jones Industrial Average has hit a ...
Read Full Story »

Valeant Pharmaceuticals Plans to Sell iNova Segment

Valeant Pharmaceuticals International Inc. (NYSE: VRX) shares made a solid gain on Thursday after the company announced the sale of its iNova Pharmaceutical business. Ultimately, Valeant will sell iNova for ...
Read Full Story »

Is Valeant for Real This Time?

When Valeant Pharmaceuticals International Inc. (NYSE: VRX) released its first-quarter financial results before the markets opened on Tuesday, it totally shocked investors. This stock has trended lower for a long ...
Read Full Story »

How Valeant Earnings Beat Estimates

Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported first-quarter 2017 results before markets opened Tuesday. The company reported quarterly diluted earnings per share (EPS) of $1.79 and revenues of $2.11 billion. ...
Read Full Story »

Disney, Snap, Whole Foods and More Key Earnings Reports Coming This Week

24/7 Wall St. has put together a preview of a few major companies scheduled to report their quarterly results this coming week. The broad markets have been pushing closer to ...
Read Full Story »

Valeant Still Has a Long Way to Go on Paying Down Its Debt

Valeant Pharmaceuticals International Inc. (NYSE: VRX) is a company that many health care and activist investors alike wish they never had heard of. On Monday, May 1, 2017, its shares were ...
Read Full Story »

Rite Aid, DryShips Stumble into Monday’s 52-Week Low Club

April 24, 2017: Here are four stocks trading with relatively heavy volume among 57 equities making new 52-week lows in Monday's session. On the NYSE, advancers led decliners by more ...
Read Full Story »